

# Akiva Diamond

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7268832/publications.pdf>

Version: 2024-02-01

9  
papers

551  
citations

1937685

4  
h-index

1720034

7  
g-index

10  
all docs

10  
docs citations

10  
times ranked

775  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B-cell lymphoma and treated with anthracyclines. <i>Hematological Oncology</i> , 2022, 40, 626-636.	1.7	3
2	Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 799-804.	0.4	1
3	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1856.	7.1	74
4	The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. <i>Thrombosis Research</i> , 2020, 194, 101-115.	1.7	454
5	Survival from time of transformation in patients with transformed lymphoma at time of diagnosis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20054-e20054.	1.6	0
6	Cardiovascular Toxicity after Therapy for Diffuse Large B Cell Lymphoma Occurs Early and Results in Decreased Overall Survival.. <i>Blood</i> , 2016, 128, 105-105.	1.4	4
7	Effect of Vitamin K on Coagulopathy of Liver Disease: A Single Center Retrospective Review. <i>Blood</i> , 2016, 128, 2583-2583.	1.4	3
8	Treatment of Diffuse Large Cell Lymphoma (DLBCL) Patients Older Than 75 Years: Higher Mortality and Risk of Complications without Increased Risk of Relapse after Treatment. <i>Blood</i> , 2016, 128, 1863-1863.	1.4	0
9	Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma Patients: Risk Factors and Outcomes. <i>Blood</i> , 2016, 128, 3611-3611.	1.4	0